Abstract
There is an increase in the incidence of onychomycosis, especially in at-risk populations. Onychomycosis is difficult to treat, as the efficacy of most antifungal agents is relatively low. Nondermatophyte molds (NDMs) and mixed infection (dermatophyte plus NDM) onychomycosis are contributing to growing antifungal resistance, as they are often underestimated and ignored due to incorrect diagnosis. There is a need for a paradigm shift in the management of onychomycosis to a patient-centered, holistic approach with an emphasis on laboratory diagnosis prior to initiating treatment, which enables the rational choice of the antifungal agent. Additionally, in the case of resistant infections, antifungal susceptibility testing is recommended. Strategies for effective management of onychomycosis include disinfection of fungal reservoirs in shoes and socks and prophylaxis posttreatment using topical antifungal agents. These measures may reduce the recurrence of onychomycosis and improve long-term clinical success.
Keywords:
Onychomycosis,
Treatment,
Management,
Superficial mycoses,
Paradigm,
Antifungal resistance
References
1.
Hazarika
D
, Jahan
N
, Sharma
A
. Changing trend of superficial mycoses with increasing nondermatophyte mold infection: a clinicomycological study at a tertiary referral center in Assam
. Indian J Dermatol
. 2019 Jul–Aug
;64
(4
):261
–5
. .2.
Warnock
DW
. Fungal diseases: an evolving public health challenge
. Med Mycol
. 2006 Dec
;44
(8
):697
–705
. .3.
Baran
R
, McLoone
N
, Hay
RJ
. Could proximal white subungual onychomycosis be a complication of systemic spread? The lessons to be learned from Maladie Dermatophytique and other deep infections
. Br J Dermatol
. 2005 Nov
;153
(5
):1023
–5
. .4.
Garcia-Rubio
R
, Cuenca-Estrella
M
, Mellado
E
. Triazole resistance in Aspergillus species: an emerging problem
. Drugs
. 2017 Apr
;77
(6
):599
–613
. .5.
Arastehfar
A
, Carvalho
A
, van de Veerdonk
FL
, Jenks
JD
, Koehler
P
, Krause
R
, COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment
. J Fungi
. 2020
;6
(2
):91
. Published 2020 Jun 24. .6.
Gupta
AK
, Stec
N
, Summerbell
RC
, Shear
NH
, Piguet
V
, Tosti
A
, Onychomycosis: a review
. J Eur Acad Derm Venereol
. 2020 Jun
;34
:1972
–90
.7.
Lipner
SR
, Scher
RK
. Onychomycosis: treatment and prevention of recurrence
. J Am Acad Dermatol
. 2019 Apr 1
;80
(4
):853
–67
. .8.
Gupta
AK
, Ryder
JE
, Johnson
AM
. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis
. Br J Dermatol
. 2004
;150
(3
):537
–44
. .9.
Gupta
AK
, Paquet
M
. Systemic antifungals to treat onychomycosis in children: a systematic review
. Pediatr Dermatol
. 2013 Jun
;30
(3
):294
–302
. .10.
Elewski
BE
. Onychomycosis: pathogenesis, diagnosis, and management
. Clin Microbiol Rev
. 1998 Jul
;11
(3
):415
–29
. .11.
Gupta
AK
, Mays
RR
, Versteeg
SG
, Piraccini
BM
, Takwale
A
, Shemer
A
, Global perspectives for the management of onychomycosis
. Int J Dermatol
. 2019
;58
(10
):1118
–29
. .12.
Westerberg
DP
, Voyack
MJ
. Onychomycosis: current trends in diagnosis and treatment
. Am Fam Physician
. 2013 Dec 1
;88
(11
):762
–70
.13.
Gupta
AK
, Versteeg
SG
, Shear
NH
, Piguet
V
, Tosti
A
, Piraccini
BM
. A practical guide to curing onychomycosis: how to maximize cure at the patient, organism, treatment, and environmental level
. Am J Clin Dermatol
. 2019 Feb
;20
(1
):123
–33
. .14.
Gupta
AK
, Elewski
BE
, Rosen
T
, Caldwell
B
, Pariser
DM
, Kircik
LH
, Onychomycosis: strategies to minimize recurrence
. J Drugs Dermatol
. 2016 Mar
;15
(3
):279
–82
.15.
Gupta
AK
, Cooper
EA
, Paquet
M
. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole
. J Cutan Med Surg
. 2013 Jun
;17
(3
):201
–6
. .16.
Tosti
A
, Piraccini
BM
, Stinchi
C
, Colombo
MD
. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up
. Dermatology
. 1998
;197
(2
):162
–6
. .17.
Drake
LA
, Shear
NH
, Arlette
JP
, Cloutier
R
, Danby
FW
, Elewski
BE
, Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
. J Am Acad Dermatol
. 1997 Nov
;37
(5 Pt 1
):740
–5
. .18.
Shemer
A
, Gupta
AK
, Kamshov
A
, Babaev
M
, Farhi
R
, Daniel
CR
, Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure
. Dermatol Ther
. 2017 Sept
;30
(5
). .19.
Sigurgeirsson
B
, Olafsson
JH
, Steinsson
JB
, Paul
C
, Billstein
S
, Evans
EG
. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study
. Arch Dermatol
. 2002 Mar
;138
(3
):353
–7
. .20.
Ghannoum
M
, Isham
N
. Fungal nail infections (onychomycosis): a never-ending story?
PLoS Pathog
. 2014
;10
(6
):e1004105
. Published 2014 Jun 5. .21.
Gupta
AK
, Renaud
HJ
, Quinlan
EM
, Shear
NH
, Piguet
V
. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses
. Am J Clin Dermatol
. 2020 Dec 22
;22
:149
–57
.22.
Pereira
LD
, Vila
T
, Borba-Santos
LP
, de Souza
W
, Navarro
M
, Rozental
S
. Activity of metal-azole complexes against biofilms of Candida albicans and Candida glabrata
. Curr Pharm Des
. 2020
;26
(14
):1524
–31
. .23.
Gupta
AK
, Daigle
D
, Carviel
JL
. The role of biofilms in onychomycosis
. J Am Acad Dermatol
. 2016 Jun
;74
(6
):1241
–6
. .24.
Córdova-Alcántara
IM
, Venegas-Cortés
DL
, Martínez-Rivera
MÁ
, Pérez
NO
, Rodriguez-Tovar
AV
. Biofilm characterization of Fusarium solani keratitis isolate: increased resistance to antifungals and UV light
. J Microbiol
. 2019 Jun
;57
(6
):485
–97
. .25.
Gupta
AK
, Drummond-Main
C
, Cooper
EA
, Brintnell
W
, Piraccini
BM
, Tosti
A
. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment
. J Am Acad Dermatol
. 2012 Mar
;66
(3
):494
–502
. .26.
Gupta
AK
, Cooper
EA
, MacDonald
P
, Summerbell
RC
. Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi
. J Clin Microbiol
. 2001 Jun
;39
(6
):2115
–21
. .27.
Summerbell
RC
. Epidemiology and ecology of onychomycosis
. Dermatology
. 1997
;194
(Suppl 1
):32
–6
. .28.
Rex
JH
, Pfaller
MA
, Walsh
TJ
, Chaturvedi
V
, Espinel-Ingroff
A
, Ghannoum
MA
, Antifungal susceptibility testing: practical aspects and current challenges
. Clin Microbiol Rev
. 2001 Oct
;14
(4
):643
–58
. Table of contents. .29.
Vandeputte
P
, Ferrari
S
, Coste
AT
. Antifungal resistance and new strategies to control fungal infections
. Int J Microbiol
. 2012
;2012
:713687
. .30.
Singh
S
, Chandra
U
, Anchan
VN
, Verma
P
, Tilak
R
. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial
. Br J Dermatol
. 2020 Jun 15
;183
:840
–6
.31.
Ebert
A
, Monod
M
, Salamin
K
, Burmester
A
, Uhrlaß
S
, Wiegand
C
, Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study
. Mycoses
. 2020 Jul
;63
(7
):717
–28
. .32.
Pai
V
, Ganavalli
A
, Kikkeri
NN
. Antifungal resistance in dermatology
. Indian J Dermatol
. 2018 Sept–Oct
;63
(5
):361
–8
. .33.
Singh
A
, Masih
A
, Khurana
A
, Singh
PK
, Gupta
M
, Hagen
F
, High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene
. Mycoses
. 2018 Jul
;61
(7
):477
–84
. .34.
Yamada
T
, Maeda
M
, Alshahni
MM
, Tanaka
R
, Yaguchi
T
, Bontems
O
, Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene
. Antimicrob Agents Chemother
. 2017 Jun 27
;61
(7
):e00115
–17
. .35.
Rudramurthy
SM
, Shankarnarayan
SA
, Dogra
S
, Shaw
D
, Mushtaq
K
, Paul
RA
, Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance
. Antimicrob Agents Chemother
. 2018 May
;62
(5
). .36.
Saunte
DML
, Hare
RK
, Jørgensen
KM
, Jørgensen
R
, Deleuran
M
, Zachariae
CO
, Emerging terbinafine resistance in Trichophyton: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection
. Antimicrob Agents Chemother
. 2019 Sept 23
;63
(10
):e01126
–19
. .37.
Monod
M
, Méhul
B
. Recent findings in onychomycosis and their application for appropriate treatment
. J Fungi
. 2019 Feb 22
;5
(1
):20
. .38.
Digby
SS
, Hald
M
, Arendrup
MC
, Hjort
SV
, Kofoed
K
. Darier disease complicated by terbinafine-resistant Trichophyton rubrum: a case report
. Acta Derm Venereol
. 2017 Apr
;97
(1
):139
–40
. .39.
Gaur
M
, Puri
N
, Manoharlal
R
, Rai
V
, Mukhopadhayay
G
, Choudhury
D
, MFS transportome of the human pathogenic yeast Candida albicans
. BMC Genomics
. 2008 Dec 3
;9
:579
. .40.
Nofal
A
, Fawzy
MM
, El-Hawary
EE
. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient
. Dermatol Ther
. 2020 Jul 15
;33
(6
):e14014
. .41.
Ahmadi
B
, Hashemi
SJ
, Zaini
F
, Shidfar
MR
, Moazeni
M
, Mousavi
B
, A case of onychomycosis caused by Aspergillus candidus
. Med Mycol Case Rep
. 2012 Jul 3
;1
(1
):45
–8
. .42.
Kimura
U
, Hiruma
M
, Kano
R
, Matsumoto
T
, Takamori
K
, Suga
Y
. Onychomycosis caused by Scopulariopsis brevicaulis: the third documented case in Japan
. J Dermatol
. 2019 May
;46
(5
):e167
–8
. .43.
Mulvaney
PM
, Telang
GH
, Jellinek
N
. Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies
. Dermatol Online J
. 2015 Sept 17
;21
(9
):21
.44.
Gallo
JG
, Woods
M
, Graham
RM
, Jennison
AV
. A severe transmissible Majocchi’s granuloma in an immunocompetent returned traveler
. Med Mycol Case Rep
. 2017 Jul 6
;18
:5
–7
. .45.
Nenoff
P
, Verma
SB
, Ebert
A
, Süß
A
, Fischer
E
, Auerswald
E
, Spread of terbinafine-resistant Trichophyton mentagrophytes type VIII (India) in Germany-“the tip of the iceberg?”
J Fungi
. 2020 Oct 5
;6
(4
):207
.46.
Gupta
AK
, Nakrieko
KA
. Trichophyton rubrum DNA strain switching increases in patients with onychomycosis failing antifungal treatments
. Br J Dermatol
. 2015 Jan
;172
(1
):74
–80
. .47.
Ksiezopolska
E
, Gabaldón
T
. Evolutionary emergence of drug resistance in Candida opportunistic pathogens
. Genes
. 2018 Sept 19
;9
(9
):461
. .48.
Morio
F
, Jensen
RH
, Le Pape
P
, Arendrup
MC
. Molecular basis of antifungal drug resistance in yeasts
. Int J Antimicrob Agents
. 2017 Nov
;50
(5
):599
–606
. .49.
Abastabar
M
, Hosseini
T
, Valadan
R
, Lagzian
M
, Haghani
I
, Aslani
N
, Novel point mutations in cyp51A and cyp51B genes associated with itraconazole and posaconazole resistance in Aspergillus clavatus isolates
. Microb Drug Resist
. 2019 Jun
;25
(5
):652
–62
. .50.
Meneau
I
, Sanglard
D
. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates
. Med Mycol
. 2005 May
;43
(Suppl 1
):S307
–11
. .51.
Ghannoum
M
. Azole resistance in dermatophytes: prevalence and mechanism of action
. J Am Podiatr Med Assoc
. 2016 Feb
;106
(1
):79
–86
. .52.
Monod
M
, Feuermann
M
, Salamin
K
, Fratti
M
, Makino
M
, Alshahni
MM
, Trichophyton rubrum azole resistance mediated by a new ABC transporter, TruMDR3
. Antimicrob Agents Chemother
. 2019 Oct 22
;63
(11
):e00863
–19
. .53.
Gupta
AK
, Taborda
VBA
, Taborda
PRO
, Shemer
A
, Summerbell
RC
, Nakrieko
KA
. High prevalence of mixed infections in global onychomycosis
. PLoS One
. 2020
;15
(9
):e0239648
. .54.
Idris
NFB
, Huang
G
, Jia
Q
, Yuan
L
, Li
Y
, Tu
Z
. Mixed infection of toe nail caused by Trichosporon asahii and Rhodotorula mucilaginosa
. Mycopathologia
. 2020 Apr
;185
(2
):373
–6
. .55.
Gawaz
A
, Weisel
G
. Mixed infections are a critical factor in the treatment of superficial mycoses
. Mycoses
. 2018 Oct
;61
(10
):731
–5
. .56.
De Doncker
PR
, Scher
RK
, Baran
RL
, Decroix
J
, Degreef
HJ
, Roseeuw
DI
, Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients
. J Am Acad Dermatol
. 1997 Feb
;36
(2 Pt 1
):173
–7
. .57.
Gupta
AK
, Paquet
M
. Management of onychomycosis in Canada in 2014
. J Cutan Med Surg
. 2015 Jun
;19
(3
):260
–73
. .58.
Al-Hatmi
AM
, Bonifaz
A
, Calderón
L
, Curfs-Breuker
I
, Meis
JF
, van Diepeningen
AD
, Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole
. Br J Dermatol
. 2015 Jul
;173
(1
):253
–5
. .59.
Noguchi
H
, Matsumoto
T
, Kimura
U
, Hiruma
M
, Kano
R
, Yaguchi
T
, Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole
. J Dermatol
. 2019
;46
(10
):911
–3
. .60.
Noguchi
H
, Matsumoto
T
, Hiruma
M
, Kimura
U
, Kano
R
, Yaguchi
T
, Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole
. J Dermatol
. 2019 Dec
;46
(12
):e446
–7
. .61.
Lurati
M
, Baudraz-Rosselet
F
, Vernez
M
, Spring
P
, Bontems
O
, Fratti
M
, Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B
. Dermatology
. 2011
;223
(4
):289
–92
. .62.
Olafsson
JH
, Sigurgeirsson
B
, Baran
R
. Combination therapy for onychomycosis
. Br J Dermatol
. 2003
;149
(Suppl 65
):15
–8
. .63.
Gupta
AK
, Cernea
M
, Foley
KA
. Improving cure rates in onychomycosis
. J Cutan Med Surg
. 2016 Nov
;20
(6
):517
–31
. .64.
Bristow
IR
, Baran
R
. Topical and oral combination therapy for toenail onychomycosis: an updated review
. J Am Podiatr Med Assoc
. 2006 Apr
;96
(2
):116
–9
. .65.
Gupta
AK
, Versteeg
SG
, Shear
NH
. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment
. J Cutan Med Surg
. 2017 Dec
;21
(6
):525
–39
. .66.
Lipner
SR
, Scher
RK
. Management of onychomycosis and co-existing tinea pedis
. J Drugs Dermatol
. 2015 May
;14
(5
):492
–4
.67.
Szepietowski
JC
, Reich
A
, Garlowska
E
, Kulig
M
, Baran
E
. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients
. Arch Dermatol
. 2006 Oct
;142
(10
):1279
–84
. .68.
Sigurgeirsson
B
, Steingrímsson
O
. Risk factors associated with onychomycosis
. J Eur Acad Dermatol Venereol
. 2004 Jan
;18
(1
):48
–51
. .69.
Gupta
AK
, Foley
K
, Versteeg
S
, Mays
R
, Villanueva
E
, John
D
. Topical and device-based treatments for fungal infections of the toenails
. Cochrane Database Syst Rev
. 2020
;1
(1
):CD012093
.70.
Markinson
BC
, Caldwell
BD
. Efinaconazole topical solution, 10%: efficacy in patients with onychomycosis and coexisting tinea pedis
. J Am Podiatr Med Assoc
. 2015 Apr 13
;105
:407
–11
. .71.
Tosti
A
, Elewski
BE
. Onychomycosis: practical approaches to minimize relapse and recurrence
. Skin Appendage Disord
. 2016 Sept
;2
(1–2
):83
–7
. .72.
Gupta
AK
, Versteeg
SG
. The role of shoe and sock sanitization in the management of superficial fungal infections of the feet
. J Am Podiatr Med Assoc
. 2019 Mar
;109
(2
):141
–9
. .73.
Zatcoff
RC
, Smith
MS
, Borkow
G
. Treatment of tinea pedis with socks containing copper-oxide impregnated fibers
. Foot
. 2008 Sept
;18
(3
):136
–41
. .74.
Gupta
AK
, Brintnell
WC
. Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis?
J Cutan Med Surg
. 2013 Aug
;17
(4
):243
–9
. .75.
Hammer
TR
, Mucha
H
, Hoefer
D
. Infection risk by dermatophytes during storage and after domestic laundry and their temperature-dependent inactivation
. Mycopathologia
. 2011 Jan
;171
(1
):43
–9
. .76.
Amichai
B
, Grunwald
MH
, Davidovici
B
, Farhi
R
, Shemer
A
. The effect of domestic laundry processes on fungal contamination of socks
. Int J Dermatol
. 2013 Nov
;52
(11
):1392
–4
. .77.
Ghannoum
MA
, Isham
N
, Long
L
. Optimization of an infected shoe model for the evaluation of an ultraviolet shoe sanitizer device
. J Am Podiatr Med Assoc
. 2012
;102
(4
):309
–13
. .78.
Dixon
HA
. The study of fungi in diseases of the skin
. Can Med Assoc J
. 1924 Nov
;14
(11
):1097
–9
.79.
Broughton
R
. Reinfection from socks and shoes in tinea pedis
. Br J Dermatol
. 1955
;67
(7
):249
. .80.
Ara
K
, Hama
M
, Akiba
S
, Koike
K
, Okisaka
K
, Hagura
T
, Foot odor due to microbial metabolism and its control
. Can J Microbiol
. 2006 Apr
;52
(4
):357
–64
. .81.
Sasagawa
Y
. Internal environment of footwear is a risk factor for tinea pedis
. J Dermatol
. 2019 Nov
;46
(11
):940
–6
. .82.
Hammer
TR
, Mucha
H
, Hoefer
D
. Dermatophyte susceptibility varies towards antimicrobial textiles
. Mycoses
. 2012 Jul
;55
(4
):344
–51
. .83.
Neely
AN
, Orloff
MM
. Survival of some medically important fungi on hospital fabrics and plastics
. J Clin Microbiol
. 2001 Sept
;39
(9
):3360
–1
. .84.
Borkow
G
. Using copper to improve the well-being of the skin
. Curr Chem Biol
. 2014 Aug
;8
(2
):89
–102
. .85.
Borkow
G
, Kanmukhla
V
, Monk
A
. Improvement to foot and skin appearance by using copper oxide impregnated socks: a report of a large scale internet based user survey
. J Cosmetol Trichol
. 2017 Jan 1
:03
.86.
Ossowski
B
, Duchmann
U
. [Effect of domestic laundry processes on mycotic contamination of textiles]
. Hautarzt
. 1997
;48
(6
):397
. .87.
Fijan
S
, Sostar-Turk
S
, Cencic
A
. Implementing hygiene monitoring systems in hospital laundries in order to reduce microbial contamination of hospital textiles
. J Hosp Infect
. 2005
;61
(1
):30
–8
. .88.
Brunton
WA
. Infection and hospital laundry
. Lancet
. 1995 Jun 17
;345
(8964
):1574
–5
. .89.
Ouf
SA
, Moussa
TA
, Abd-Elmegeed
AM
, Eltahlawy
SR
. Anti-fungal potential of ozone against some dermatophytes
. Braz J Microbiol
. 2016 Sept
;47
(3
):697
–702
. .90.
Gupta
AK
, Brintnell
W
. Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system
. J Dermatolog Treat
. 2014 Jun
;25
(3
):251
–5
. .91.
Reed
NG
. The history of ultraviolet germicidal irradiation for air disinfection
. Public Health Rep
. 2010 Jan–Feb
;125
(1
):15
–27
. .92.
Katara
G
, Hemvani
N
, Chitnis
S
, Chitnis
V
, Chitnis
DS
. Surface disinfection by exposure to germicidal UV light
. Indian J Med Microbiol
. 2008 Sept
;26
(3
):241
–2
. .93.
Dai
T
, Tegos
GP
, Rolz-Cruz
G
, Cumbie
WE
, Hamblin
MR
. Ultraviolet C inactivation of dermatophytes: implications for treatment of onychomycosis
. Br J Dermatol
. 2008 Jun
;158
(6
):1239
–46
. .94.
Nematollahi
AR
, Badiee
P
, Nournia
E
. The Efficacy of ultraviolet irradiation on Trichophyton species isolated from nails
. Jundishapur J Microbiol
. 2015 Jun
;8
(6
):e18158
. .95.
Dai
T
, Vrahas
MS
, Murray
CK
, Hamblin
MR
. Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections?
Expert Rev Anti Infect Ther
. 2012 Feb
;10
(2
):185
–95
. .96.
Budihardja
D
, Mayser
P
. The effect of microwave irradiation on the vitality of various dermatophytes
. Mycoses
. 2014 Apr
;57
(4
):209
–13
. .97.
Gupta
AK
, Ryder
JE
. How to improve cure rates for the management of onychomycosis
. Dermatol Clin
. 2003 Jul
;21
(3
):499
–vii
. vii. .98.
Sigurgeirsson
B
. Prognostic factors for cure following treatment of onychomycosis
. J Eur Acad Dermatol Venereol
. 2010 Jun
;24
(6
):679
–84
. .99.
Sakamoto
M
, Sugimoto
N
, Kawabata
H
, Yamakawa
E
, Kodera
N
, Pillai
R
, Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails
. J Drugs Dermatol
. 2014 Nov 1
;13
(11
):1388
–92
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
